Table 2 Details of polymyxin B hemoperfusion
Characteristics | Early administration group (n = 40) | Late administration group (n = 42) | P value |
|---|---|---|---|
Time from ICU admission to the first session of PMX-HP, min, median (IQR) | 110 (60–180) | 465 (328–748) |  < 0.0001 |
Duration of the first session of PMX-HP, min, median (IQR) | 1035 (518–1331) | 995 (553–1390) | 0.93 |
Blood flow rate during the 1st session of PMX-HP, ml/min, median (IQR) | 100 (80–100) | 100 (80–100) | 0.42 |
Anticoagulation for hemoperfusion during first session of PMX-HP | Â | Â | 0.56 |
Nafamostat mesylate, n (%) | 38 (95) | 38 (90) | Â |
Unfractionated heparin, n (%) | 2 (5) | 3 (7) | Â |
None, n (%) | 0 (0) | 1 (2) | Â |
Premature interruption due to circuit clotting during the first session of PMX-HP, n (%) | 15 (38) | 10 (24) | 0.23 |
Implementation of the second session of PMX-HP, n (%) | 17 (43) | 19 (45) | 0.83 |
Time from ending the first session to starting the second session of PMX-HP, min, median (IQR)a | 110 (18–384) | 115 (10–246) | 0.66 |
Duration of second session of PMX-HP, min, median (IQR)a | 840 (514–1485) | 1290 (1187–1566) | 0.16 |